Acer Rubrum Pollen Acer Saccharum Pollen Agrostis
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acer Rubrum Pollen Acer Saccharum Pollen Agrostis
- Multi-Allergen Immunotherapy Extract Complex: Allergen Desensitization – No TxGNN Predictions Available
Multi-Allergen Immunotherapy Extract Complex: Allergen Desensitization – No TxGNN Predictions Available
One-Sentence Summary
This candidate is a complex multi-component allergen extract mixture comprising 69 botanical antigens — spanning tree pollens, grass pollens, weed pollens, and herbal botanicals — of the type used in subcutaneous allergen immunotherapy (SCIT) for allergic rhinitis and polysensitized allergic disease. The TxGNN pipeline returned no predicted new indications for this candidate, most likely because the multi-ingredient string could not be resolved to a single DrugBank entity or knowledge-graph node. Without a valid prediction, a formal repurposing evaluation cannot proceed at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergen immunotherapy / allergy desensitization (inferred from composition) |
| Predicted New Indication | None – TxGNN generated no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A – pipeline did not produce a candidate |
| US Market Status | Not marketed (no NDA records found) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This candidate is not a single molecular entity but a 69-component allergen mixture whose ingredients include:
- Tree pollens (22 species): Acer rubrum, Acer saccharum, Ailanthus altissima, Alnus rubra, Betula nigra, Carya tomentosa, Celtis occidentalis, Fagus grandifolia, Fraxinus americana, Juglans regia, Juniperus ashei/scopulorum/virginiana, Ligustrum vulgare, Liquidambar styraciflua, Morus alba, Picea pungens, Pinus strobus, Platanus occidentalis, Populus alba/deltoides/nigra/tremuloides, Pseudotsuga menziesii, Salix nigra, Ulmus americana/pumila
- Grass pollens (15 species): Agrostis gigantea, Anthoxanthum odoratum, Avena sativa, Bromus inermis, Dactylis glomerata, Festuca pratensis, Lolium multiflorum/perenne, Pascopyrum smithii, Phalaris arundinacea, Phleum pratense, Poa pratensis, Sorghum halepense, Triticum aestivum, Zea mays
- Weed pollens (21 species): Amaranthus retroflexus/spinosus/tuberculatus, Ambrosia acanthicarpa, Artemisia absinthium/ludoviciana/tridentata/vulgaris, Atriplex canescens/confertifolia, Bassia scoparia, Chenopodium album, Cyclachaena xanthifolia, Iva annua, Plantago lanceolata, Rumex acetosella, Salsola tragus, Sarcobatus vermiculatus, Solidago canadensis, Urtica dioica, Xanthium strumarium
- Herbal botanical components (5): Baptisia tinctoria root, Echinacea (unspecified), Fenugreek leaf, Goldenseal, Myrrh, Phytolacca americana root
The TxGNN knowledge graph is built around single INN molecules mapped to DrugBank IDs. A multi-ingredient string of this length cannot be resolved to any DrugBank node, so the KG traversal and DL scoring steps both returned null results. This is a pipeline limitation, not a signal that the product has no repurposing potential.
The five herbal components — especially Echinacea, Goldenseal (Hydrastis canadensis), and Phytolacca — have established immunomodulatory properties studied independently, but they were queried as part of the composite string and were not individually scored.
Safety Considerations
Please refer to the package insert for safety information.
Note: No TFDA registration was found for this product combination. Standard allergen immunotherapy precautions apply: anaphylaxis risk with dose escalation, requirement for post-injection observation periods, and contraindication in patients on beta-blockers or with severe asthma.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline cannot process a 69-component allergen mixture as a single entity; without a resolvable DrugBank ID and a scored prediction, there is no repurposing hypothesis to evaluate.
To proceed, the following is needed:
- Decompose the mixture: Re-submit each individual component (e.g., Phleum pratense pollen → DB01161, Echinacea → DB00584) as separate single-drug queries so TxGNN can score each independently.
- Identify the intended therapeutic entity: Determine whether the repurposing question concerns the full allergen mix (immunotherapy application) or one of the herbal botanicals within it (e.g., Goldenseal/berberine, Echinacea polysaccharides).
- Resolve DrugBank mapping: Manually map the components with known DrugBank IDs before re-running the KG prediction pipeline.
- Obtain regulatory data: If any individual component has TFDA or FDA NDA registration, retrieve the package insert for MOA and safety data.
- Re-run pipeline per component: After decomposition, generate individual Evidence Packs and aggregate findings into a coherent repurposing landscape for the botanicals of interest.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.